Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis

被引:0
|
作者
Satoshi Watanabe
Junta Tanaka
Takeshi Ota
Rie Kondo
Hiroshi Tanaka
Hiroshi Kagamu
Kosuke Ichikawa
Jun Koshio
Junko Baba
Takao Miyabayashi
Ichiei Narita
Hirohisa Yoshizawa
机构
[1] Niigata University Medical and Dental Hospital,Department of Medicine (II)
[2] Niigata University Medical and Dental Hospital,Bioscience Medical Research Center
来源
BMC Cancer | / 11卷
关键词
Overall Survival; Gefitinib; Erlotinib; NSCLC Patient; Disease Control Rate;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 50 条
  • [1] Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis
    Watanabe, Satoshi
    Tanaka, Junta
    Ota, Takeshi
    Kondo, Rie
    Tanaka, Hiroshi
    Kagamu, Hiroshi
    Ichikawa, Kosuke
    Koshio, Jun
    Baba, Junko
    Miyabayashi, Takao
    Narita, Ichiei
    Yoshizawa, Hirohisa
    BMC CANCER, 2011, 11
  • [2] Clinical Responses to EGFR-tyrosine Kinase Inhibitor Retreatment in Non-small Cell Lung Cancer Patients Who Benefited Prior Gefitinib Therapy
    Watanabe, S.
    Saida, Y.
    Ichikawa, K.
    Koshio, J.
    Baba, J.
    Miura, S.
    Tanaka, J.
    Kagamu, H.
    Narita, I.
    Yoshizawa, H.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S618 - S619
  • [3] CLINICAL RESPONSES TO GEFITINIB RETREATMENT IN NON-SMALL-CELL-LUNG-CANCER ADENOCARCINOMA PATIENTS WHO BENEFITED FROM PRIOR EFFECTIVE GEFITINIB THERAPY: A RETROSPECTIVE ANALYSIS
    Li, Junling
    Yan, Wang
    Yuankai, Shi
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1291 - S1292
  • [4] A RETROSPECTIVE ANALYSIS OF THE CLINICAL RESPONSES TO EGFR-TYROSINE KINASE INHIBITOR (EGFR-TKI) CONTINUOUS TREATMENT BEYOND SINGLE SITE DISEASE PROGRESSION IN METASTATIC NON-SMALL CELL LUNG CANCER PATIENTS WHO BENEFITED FROM PRIOR EGFR-TKI THERAPY
    Parra, Hector J. Soto
    Chiari, Rita
    Bearz, Alessandra
    Cavina, Raffaele
    Spadaro, Pietro
    Latteri, Fiorenza
    Bordonaro, Roberto
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1254 - S1254
  • [5] Overcoming resistance to EGFR-Tyrosine Kinase Inhibitor therapy in non-small cell lung cancer
    Sierra, Rafael
    Chang, Anderson
    Moffat, Jason
    Neel, Benjamin G.
    Tsao, Ming-Sound
    CLINICAL CANCER RESEARCH, 2012, 18 (03)
  • [6] Overcoming resistance to EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer
    Sierra, J. Rafael
    Chang, Anderson
    Moffat, Jason
    Neel, Benjamin G.
    Tsao, Ming-Sound
    CANCER RESEARCH, 2012, 72
  • [7] CLINICAL ANALYSIS OF AFATINIB IN EGFR-TYROSINE KINASE INHIBITOR NAIVE PATIENTS WITH NON-SMALL CELL LUNG CANCER HABORING EGFR MUTATIONS
    Nasu, Shingo
    Takata, So
    Masuhiro, Kentaro
    Morita, Satomu
    Iwata, Kaori
    Ryota, Noriko
    Okada, Yukari
    Tokuoka, Yoshie
    Ueda, Yuki
    Kumode, Akinori
    Usui, Naoko
    Tanaka, Ayako
    Shiroyama, Takayuki
    Morishita, Naoko
    Suzuki, Hidekazu
    Okamoto, Norio
    Hirashima, Tomonori
    RESPIROLOGY, 2017, 22 : 114 - 114
  • [8] Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study
    Chang, Gee-Chen
    Tseng, Chien-Hua
    Hsu, Kuo-Hsuan
    Yu, Chong-Jen
    Yang, Cheng-Ta
    Chen, Kun-Chieh
    Yang, Tsung-Ying
    Tseng, Jeng-Sen
    Liu, Chien-Ying
    Liao, Wei-Yu
    Hsia, Te-Chun
    Tu, Chih-Yen
    Lin, Meng-Chih
    Tsai, Ying-Huang
    Hsieh, Meng-Jer
    Wu, Wen-Shuo
    Chen, Yuh-Min
    LUNG CANCER, 2017, 104 : 58 - 64
  • [10] EGFR-TYROSINE KINASE INHIBITOR (TKI) RECHALLENGE WITH BEVACIZUMAB IN EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
    Otsuka, K.
    Hata, A.
    Kato, R.
    Takeshita, J.
    Okuda, C.
    Kaji, R.
    Masago, K.
    Fujita, S.
    Katakami, N.
    ANNALS OF ONCOLOGY, 2014, 25